72 results about "Comorbidity" patented technology

Methods, systems, and apparatus for assessing a state of an epilepsy disease or a comorbidity thereof are provided. The methods comprise receiving at least one autonomic index, neurologic index, stress marker index, psychiatric index, endocrine index, adverse effect of therapy index, physical fitness index, or quality of life index of a patient; comparing the at least one index to at least one reference value; and assessing a state of an epilepsy disease or a body system of the patient based on the comparison. A computer readable program storage device encoded with instructions that, when executed by a computer, perform the method described above is also provided. A medical device system capable of implementing the method described above is also provided.

Methods, systems, and apparatus for assessing a state of a comorbidity associated with a primary disease are provided. The methods comprise receiving at least one autonomic index, neurologic index, stress marker index, psychiatric index, endocrine index, adverse effect of therapy index, physical fitness index, or quality of life index of a patient; comparing the at least one index to at least one reference value; and assessing a state of a body system of the patient that is a site of the comorbidity, based on the comparison. A computer readable program storage device encoded with instructions that, when executed by a computer, perform the method described above is also provided. A medical device system capable of implementing the method described above is also provided.

The present invention provides devices and methods for attachment of an endolumenal gastrointestinal device, such as an artificial stoma device, a gastrointestinal bypass sleeve or other therapeutic or diagnostic device, within a patient's digestive tract. In one application of the invention, an endolumenal bypass sleeve is removeably attached in the vicinity of the gastroesophageal junction to treat obesity and/or its comorbidities, such as diabetes. The bypass sleeve may be at least partially deployed by eversion.

The present invention provides devices and methods for attachment of an endolumenal gastrointestinal device, such as an artificial stoma device, a gastrointestinal bypass sleeve or other therapeutic or diagnostic device, within a patient's digestive tract. In one application of the invention, an endolumenal bypass sleeve is removeably attached in the vicinity of the gastroesophageal junction to treat obesity and/or its comorbidities, such as diabetes. The bypass sleeve may be at least partially deployed by eversion.

The present invention provides devices and methods for attachment of an endolumenal gastrointestinal device, such as an artificial stoma device, a gastrointestinal bypass sleeve or other therapeutic or diagnostic device, within a patient's digestive tract. In one application of the invention, an endolumenal bypass sleeve is removeably attached in the vicinity of the gastroesophageal junction to treat obesity and/or its comorbidities, such as diabetes. The bypass sleeve may be at least partially deployed by eversion.

Methods and devices reroute chyme to induce intestinal brake in order to improve the effectiveness of bariatric surgical procedures and to improve comorbidity resolution. A bowel is manipulated to provide a shortened path for chyme to travel to the ileum. These methods and devices of rerouting chyme to induce intestinal brake may comprise one or more of a surgical procedure, an implanted device, or a combination of an implant with an improved surgical procedure.

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET_A) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ET_A receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ET_A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ET_A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET_A receptor antagonist.

A pure traditional Chinese medicine preparation for treating cardiovascular diseases is characterized in that the pure traditional Chinese medicine preparation is prepared by traditional Chinese medicine raw materials with the following parts by weight: 5-10 parts of safflower, 10-20 parts of motherwort herb, 4-8 parts of danshen root, 4-8 parts of Szechuan lovage rhizome, 2-4 parts of medicinal cyathula root, 3-6 parts of peach seed, 2-4 parts of trogopterus dung, 2-4 parts of common burreed rhizome, 2-4 parts of zedoary, 2-4 parts of turmeric, 1-2 parts of dragon blood, 3-6 parts of clematis root, 2-4 parts of gentiana macrophylla, 2-4 parts of heracleum hemsleyanum michaux, 2-4 parts of radix stephaniae tetrandrael, 2-4 parts of sea-ear shell, 2-4 parts of oyster shell, 2-4 parts of puncturevine caltrop fruit, 3-6 parts of uncaria, 1-2 parts of stiff silkworm, 0.2-0.4 part of scorpion, 4-8 parts of rhubarb, 2-4 parts of ephedra herb, 2-4 parts of pepperweed seed, 2-4 parts of bitter apricot seed, 2-4 parts of sessile stemona root, 4-8 parts of unibract fritillary bulb, 2-4 parts of snakegourd fruit, 2-4 parts of arisaema cum bile, 2-4 parts of pinellia tuber, 2-4 parts of nutgrass galingale rhizome, 2-4 parts of rhizoma corydalis, 2-4 parts of Chinese eaglewood, 2-4 parts of cassia seed, 2-4 parts of common selfheal fruit-spike, 1-2 parts of cicada slough, 3-6 parts of honeysuckle flower, 2-4 parts of chrysanthemum, 3-6 parts of baical skullcap root, 2-4 parts of golden thread, 2-4 parts of tree peony bark, 4-8 parts of red paeony root, 4-8 parts of tuber fleeceflower root and 4-8 parts of membranous milk vetch root. The pure traditional Chinese medicine preparation is used for treating various cardiovascular diseases, the sequelae and the complications thereof.

The invention relates to a traditional Chinese medicine for treating diabetes mellitus and a preparation method thereof. The technical scheme is as follows: the traditional Chinese medicine comprisesthe following raw medical materials: astragali semen, trichosanthes, agrimony, scouring rush, astragalus, rhizoma coptidis, yam, schisandra chinensis, purslane, achyranthes aspera, azolla, salvia, gegen, white peony roots, anemarrhena, fleece-flower roots, gypsum, dodders, buntal, rehmanniae, hen egg yolk, ball cactus and silkworm chrysalis. The preparation method comprises the following steps: taking the raw medical materials by weight portions; grinding and mixing the silkworm chrysalis with the ground hen egg yolk; adding liquor; heating, refluxing, cooling and soaking to prepare medical liquid A; taking the astragalus and the rhizoma coptidis; adding liquor; heating, refluxing, cooling, pulping and soaking to prepare medical liquid B; soaking and pulping the other medical materials inthe liquor; additionally adding liquor to soak and prepare medical liquid C; and mixing the medical liquid A, the medical liquid B and the medical liquid C. The invention has the functions of nourishing yin, clearing heat, activating blood and warming yang, treats both principal and secondary aspects of the disease, not only has favorable treatment effect for the diabetes mellitus, but also has obvious treatment effect on diabetes mellitus complications.

The present invention provides polypeptides which are predominately expressed in visceral adipose tissue which can be used as markers for the measurement of the levels of visceral adipose tissue in a subject. The invention also provides methods for the measurement of the levels of visceral adipose tissue by obtaining a biological sample and detecting and/or measuring the increase of one or more polypeptides as disclosed herein. Screening methods relating to agonists and antagonists of the specific polypeptides disclosed herein are provided. Antibodies may also be raised against these polypeptide markers for the detection and/or treatment of metabolic syndrome related comorbidities.

Systems and methods for healthcare assurance system are provided. A first set of confidential health information for an identified patient may be accessed, may be derived from a first data source, and may include first medical indicia corresponding to an indication of a first health condition and/or an indication of a first healthcare service. A second set of confidential health information may be accessed, may be derived from a second data source, and may include second medical indicia corresponding to an indication of a second health condition and/or an indication of a second healthcare service. Healthcare rules that include criteria indicating comorbidity conditions may be accessed. The first and second sets of confidential health information may be correlated to the healthcare rules. A comorbidity condition may be identified based on the first medical indicia, the second medical indicia, and the correlating. A prompt regarding the comorbidity condition may be provided.

A mapping matrix, which maps from original features of an electronic health record database to higher level latent factors, is initialized. For each of one or more target diseases, regression coefficients are updated over the higher level latent factors, based on said initialized mapping matrix, a data matrix containing said original features, and a label vector of corresponding responses. Said mapping matrix is updated based on said updated regression coefficients. Said steps of updating said regression coefficients and updating said mapping matrix are repeated until convergence is achieved, to obtain a final mapping matrix and a final set of regression coefficients.

The present invention relates to methods of treating subjects preparing to undergo surgery or methods of treating chronic disease and methods for reducing transfusions and a computer readable storage medium and a physical computing device for carrying out these methods which include: a) receiving a profile of said subject, in a physical computing device, including a level of hemoglobin of said subject, level of creatinine of said subject, and information regarding current or past history of disease; b) applying said level of hemoglobin and said level of creatinine, in said physical computing device, to determine level of transfusion risk; c) applying said information regarding current or past history of disease of said subject, in said physical computing device, to determine level of comorbidity; d) applying said level of hemoglobin, said level of transfusion risk, and said level of comorbidity, in said physical computing device, to determine a patient care plan.

A health-care food for protecting gastric mucosa contains chitosan (15-95 wt.%) and carragheenin (5-85 wt.%), and is prepared from the edible marine living things through extraction and separation of effective components. Its advantages are high effect and no by-effect.

This invention comprises an extract of Artemisia dracunculus that can be used for the treatment and prevention of diabetes, diabetic complications, metabolic syndrome and other comorbidities that share the underlying commonality of insulin resistance. The invention includes the identity of six compounds from the extract that contribute to the activity of the extract by inhibiting protein tyrosine phosphatase-1B (PTP-1B) activity, phosphoenolpyruvate carboxykinase (PEPCK) gene expression or aldose reductase activity (ALR2). The compounds include 4,5-Di-O-caffeoylquinic acid, davidigenin, 6-demethoxycapillarisin, 2′,4-dihydroxy-4′-methoxydihydrochalcone, 2′,4′-dihydroxy-4-methoxdihydrochalcone and sakuranetin.

A system for individualized treatment of a tissue condition with acoustic pressure shocks includes personalized determination and automatic adjustment of a shock wave treatment regimen or shock wave dosage to be administered for personalized treatment based on factors such as a patient's comorbidities, state of the tissue condition, individual physical characteristics and lifestyle parameters.

The invention discloses a cross-platform clinical big data analysis and display system. The system comprises a servo, an academic-edition website, a trade-edition website, an academic-edition embedded application and a trade-edition embedded application. The servo comprises a clinical medical data collection subsystem, an expert verification subsystem, an automatic acceleration subsystem, an automatic regressive diagnosis subsystem and an automatic statistics subsystem. Through the system, efficient and precise statistical analysis of clinical disease big data can be realized, medical big data can be utilized to perform longitudinal and transverse research quickly, data results can be recombined objectively, multiple models can be utilized for statistical analysis and display of the relation between different gendersand comorbidity, the relation between different age groups and comorbidity, the relation between diseases, the relation between drugs and diseases and the relation between drugs and operations, past theories can be verified, new theories can be proposed, and the system can be applied to the fields of medical treatment, insurance, medical research, pharmaceuticals, etc.